Drug Discovery Global Market Report 2023 – By Drug Type (Small Molecule, Large Molecule), By Process (Target Selection, Target Validation, Hit To Lead Identification, Lead Optimization, Candidate Validation), By Technology (High Throughput Screening, Spectroscopy, Combinatorial Chemistry, Biochips, Pharmacogenomics and Pharmacogenetics, Bioinformatics, Metabolomics, Nanotechnology, Other Technologies), By Therapeutic Area (Oncology, Neurology, Infectious and Immune System Diseases, Digestive System Diseases, Cardiovascular Diseases, Diabetes, Respiratory Disease, Other Therapeutic Areas), By End User (Pharmaceutical Companies, CROs, Other End Users) – Market Size, Trends, And Global Forecast 2023-2032

Cell culture is a process for developing substrates for the safe production of viral vaccines. 3D cell culture is an in vitro technique wherein the cells can grow in an artificially created environment. The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The main types of 3D cell culture technologies are scaffold-based, scaffold-free, and 3D bioreactors. The 3D bioreactors are small plastic cylinder chambers designed specifically for growing cells in three dimensions. The various scaffold-based technologies include hydrogels, polymeric scaffolds, micropatterned surface microplates and the different scaffold-free technologies are hanging drop microplates, spheroid microplates, microfluidic 3d cell culture, magnetic levitation and 3D bioprinting. The technologies are applied for cancer research, stem cell research, drug discovery, and regenerative medicine that are used by research laboratories and institutes, biotechnology and pharmaceutical companies, hospitals and diagnostic centers, and other end users. The global 3D cell culture technologies market is segmented – 1) By Type: Scaffold-based, Scaffold-free, 3D Bioreactors 2) By End Users: Research Laboratories and Institutes, Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostic Centers, Other End Users 3) By Scaffold-based: Hydrogels, Polymeric scaffolds, Micropatterned Surface Microplates 4) By Scaffold-free: Hanging Drop Microplates, Spheroid Microplates, Microfluidic 3D Cell Culture, Magnetic Levitations & 3D Bioprinting 5) By Application: Cancer Research, Stem Cell Research, Drug Discovery, Regenerative Medicine The global 3d cell culture technologies market size grew from $2.39 billion in 2022 to $2.83 billion in 2023 at a compound annual growth rate (CAGR) of 18.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the 3d cell culture technologies market is expected to grow from $5.65 billion in 2027 at a CAGR of 18.9%. The increasing requirement for organ transplantation is driving the 3D Cell Culture Technologies Market. 3D cell culture helps in forming a three-dimensional structure which further helps in mimicking the tissue or organ and therefore helps in organ transplantation. 3D cell structures are capable of tissue and organ regeneration as well as providing the provision for drug toxicology screening. For instance, according to the Organ Procurement and Transplantation network, an American non-profit organization administering the organ transplantation in the US, 41,354 organ transplantations were performed in the United States in 2021 which was an increase of 5.9% as compared to 2020 and the number exceeded 40,000 mark for the first time ever. Major players in the 3D cell culture technologies market are Becton Dickinson, Corning Incorporation, Eppendorf, GE Healthcare, Merck KGaA, Thermo Fisher Scientific, Lonza, HiMedia Laboratories, Agilent Technologies, PromoCell GmbH, CellGenix GmbH, InvivoGen, Greiner Bio-One, Irvine Scientific, Cell Culture Company (CCC) LLC., Sera Care Life Sciences Incorporation, American Type Culture Collection, Miltenyi Biotec, AITbiotech, ESSEN, Sigma-Aldrich, Bel-Art, MilliporeSigma, Cellgenix, Sumitomo Bakelite, EMD Millipore, AffymetrixInc., VWR International, LLC., WHEATON IndustriesInc., and Sartorius A. The possibility of contaminating the cells is restricting the 3D Cell Culture technologies market. Contamination of the cell culture refers to the presence of bacteria, moulds, yeasts, viruses, and mycoplasma that can adversely affect the cell culture. Contamination usually occurs when the cells are mishandled or due to the lack of adequate care, as a result the process of regeneration may get affected. According to a study conducted by Yale and Tuff's university, it was found that 3D cultures are more complex than 2D cell cultures and they require a more controlled cellular environment in order to mimic structures for tissue or organ transplants. Therefore, probability of cell culture contamination is relatively higher in 3D cell cultures. Implementing the latest technology is the latest trend in the 3D Cell culture market. For example, various companies have adopted one such advancement in the market for 3D cell culture, this is the use of the vivo/vitro environment. Cell expansion and interactions under 2D are not appropriate in vitro models but when compared with 3D cell culture technique, it offers a better cell culture environment. The Vitro environment enables researchers or doctors to conduct the procedure in a controlled environment outside the organism. This procedure is gaining importance as it plays a vital role in monitoring the health of patients. FDA approved Biotek's 3D cell expansion system to be used as a medical device. It also approved Biotek's Polycaprolactone (PCL) which is a biodegradable polyester material that is used in many FDA-approved implants and drug delivery devices. FDA regulates the cell culture technologies under title 21, sec 864.2240. FDA states that cell and tissue culture technologies should be labelled or mentioned as sterile, or else they would be removed from the good manufacturing practice of the quality system. Each technology unit should maintain procedures to receive, review, and evaluate complaints. These procedures should also include consistent documentation of the receipts. In May 2021, CELLINK Group, a USA-based start-up that designs and supplies technologies and services to enhance biology research, has acquired Visikol Corporation for $7.5 million. With this acquisition, CELLINK made an entrance into the contract research market. Visikol Corp., an American contract research services company that provides pharma and biotech industries with leading services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology. North America was the largest region in the 3D cell culture technologies market in 2022. Western Europe was the second largest region in the 3D cell culture technologies market share. The regions covered in the global 3D cell culture technologies market report analysis are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the 3D cell culture technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The 3D cell culture technologies market consists of sales of 3D cell culture technologies such as microfluidics, hydrogels scaffolds, scaffold-free 3D cell culture techniques, spheroids, cube, spherical droplet, stacked plate, magnetic bead, organ-on-chips and other technologies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The 3D cell culture technologies market research report is one of a series of new reports from The Business Research Company that provides 3D cell culture technologies market statistics, including 3D cell culture technologies industry global market size, regional shares, competitors with a 3D cell culture technologies market share, detailed 3D cell culture technologies market segments, market trends and opportunities, and any further data you may need to thrive in the 3D cell culture technologies industry. This 3D cell culture technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell based assays are experimental tools that are designed to study reactions taking place inside the cells. These assays are used to study a mechanism or process of cellular function. The main product and services for cell based assays are consumables, instruments, services, and software. Consumables are products that are used up or depleted during their use. The various instruments used are microplates, microplate readers, high throughput screening systems, and liquid handling systems. Different consumables include reagents and media, cells and cell lines, probes, and labels. The several technology types of cell based assays are automated handling, flow cytometry, label-free detection, high-throughput screening, and others, and they are applied for drug discovery, basic research, ADME studies, predictive toxicology, and other purposes. The different end users include pharmaceutical and biotechnology companies, academic and government research institutes, contract research organizations (CRO) and others. The global cell based assays market is segmented - 1) By Product & Service: Consumables, Instruments, Services, Software 2) By Application: Drug Discovery, Basic Research, Adme Studies, Predictive Toxicology, Other Applications 3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Government Research Institutes, Contract Research Organizations (CRO), Other End Users 4) By Technology: Automated Handling, Flow Cytometry, Label-Free Detection, High-Throughput Screening, Other Technologies 5) By Consumables: Reagents And Media, Cells And Cell Lines, Probes And Labels 6) By Instruments: Microplates, Microplate Readers, High Throughput Screening, Liquid Handling Systems The global cell based assays market size will grow from $22.58 billion in 2022 to $24.61 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global cell based assays is expected to grow to $36.22 billion in 2027 at a CAGR of 10.1%. Research with cell based arrays is increasing with evolution and there is a definite need to move to more predictive cellular models for drug discovery in order to control the last-stage drug failures. The pharmaceutical industries’ need to efficiently commercialize drugs in order to overcome expensive failures in the last stages is a driving force in cell-based assay innovation. Failure of investigational new drug (IND) Phase III clinical trials results in a loss of several hundred million dollars to that company. For instance, according to report by Sigma, the return on investment for pharmaceutical companies could drop to 5% considering the current level of late-stage failures, and is an unacceptable level for most companies. Major improvements to high-content systems and data analysis from the cell based assays enable scientists to extract a more information about the cellular response and help take informed decisions during drug discovery, and further driving the growth of the cell based arrays market. Major players in the cell based assays market are Thermo Fisher, Danaher, Becton, Dickinson and Company, GE Healthcare, Merck, Perkinelmer, Promega, Lonza, Charles River Laboratories and Cell Signaling Technology. High cost of instruments is the major factor restraining the global cell based assays market. High price of the instrumentation will reduce the return on investments (ROI) owing to low adaptation. For example, Biotek developed HCA (high content analysis) instruments and are expensive and reserved for industrial end-users or core labs which have sufficient capital budgets. This restricts the low budgeted end-users to use cell based assays to its full potential, thereby hampering the growth of the market. Researchers are inclining towards early phase predictive toxicity testing that prevent late-stage drug failures. Predictive cell toxicity assays are being scaled up to increase screening of compounds in the early phases of drug development, reducing the cost of failure. For instance, Creative Bioarray, a biotech company provides a range of in vitro toxicity services to check drug-induced toxicities that save time and cost by reducing the chance of failure in earlier stage. These advances will make clinical testing easy and reduce the cost of operation. In May 2022, Cell Carta, a Canada-based provider of precision medicine laboratory services, acquired next-generation immune-MRM assays from Precision assays for an undisclosed amount. The acquisition will solidify Cell Carta’s position in the proteomics vertical and help it better serve the customers. Precision Assays is a US-based provider of next-generation targeted proteomics testing solutions. North America was the largest region in the cell based assays market in 2022. Western Europe was the second largest region in the global cell based assays market share. The regions covered in the global cell based assays market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cell based assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cell based assays market consists of sales of reagents, cell lines, microplates, microplate, assay kits, probes and labels. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The cell based assays market research report is one of a series of new reports from The Business Research Company that provides cell based assays market statistics, including cell based assays industry global market size, regional shares, competitors with a cell based assays market share, detailed cell based assays market segments, market trends and opportunities, and any further data you may need to thrive in the cell based assays industry. This cell based assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Laboratory automation systems refer to the use of instruments to carry out laboratory tasks with a minimum of human involvement. Clinical laboratories operate more efficiently because of laboratory automation, which helps to standardise tests. The main equipment and software of laboratory automation systems are automated liquid handling, microplate readers, standalone robots, automated storage and retrieval systems, software, informatics, and other equipment. The microplate reader is an instrument that is used to measure biological, chemical or physical reactions of analytes within the wells of the microplate. The various types include modular automation, total lab automation that is used in applications such as drug discovery, clinical diagnostics, genomics solutions, proteomics solutions, and other applications. The end users covered in this market are biotechnology and pharmaceutical industries, research institutes, hospitals, private labs, and academic institutes. The global laboratory automation systems market is segmented - 1) By Equipment & Software: Automated Liquid Handling, Microplate Readers, Standalone Robots, Automated Storage And Retrieval Systems, Software And Informatics, Other Equipment 2) By Application: Drug Discovery, Clinical Diagnostics, Genomics Solutions, Proteomics Solutions, Other Applications 3) By End User: Biotechnology And Pharmaceutical Industries, Research Institutes, Hospitals And Private Labs, Academic Institutes 4) By Type: Modular Automation, Total Lab Automation The global laboratory automation systems market size grew from $5.87 billion in 2022 to $6.21 billion in 2023 at a compound annual growth rate (CAGR) of 5.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The laboratory automation systems market is expected to grow from $7.43 billion in 2027 at a CAGR of 4.6%. Increased demand for microbiology testing and standardization of sample-collection devices for microbiology culture has driven the adoption of automated laboratory systems for culture-based laboratory testing in clinical microbiology. Culture-based microbiology laboratory testing by manual methods is being replaced by automated methods with the help of total laboratory automation. For instance, popular systems such as Becton Dickinson’s Kiestra TLA, Copan’s WASPLab, and others enable total laboratory automation (TLA) for culture-based microbiology testing. The potential to affect laboratory efficiency, turnaround time, and the overall quality of culture-based microbiology testing, is driving the automated laboratory systems market growth. Major players in the laboratory automation systems market are Tecan Group, Perkinelmer, Thermo Fisher Scientific, Agilent Technologies, Danaher, Qiagen, Roche, Abbott, Siemens, and Eppendorf. The laboratory automation systems market growth is limited due to a severe shortage of skilled and trained healthcare professionals for operating the advanced laboratory equipment which requires specialized skillsets. These skillsets are limited to some hospitals, research organizations, and medical equipment companies in the USA and Europe, this is expected to be a major restraint on the market. 40% of the healthcare industry was facing difficulties in hiring process development staff due to a shortage of talent. According to the American Society for Clinical Pathology (ASCP) survey, average job-vacancy rates exceed 50% in some states. This shortage also led to a rise in competition and salaries for the limited talent pool available, thereby further limiting the laboratory automation systems market growth. The hospital laboratories are increasingly adopting RFID technology for laboratory automation systems due to its better productivity and product quality reduced costs for technology, error reduction, faster delivery of samples, and reduced human intervention. Radio Frequency Identification (RFID) technology is an automatic system of identification based on wireless communication, consisting of a tag and a reader which can communicate through radiofrequency. RFID technology is similar to bar code technology but is more beneficial as it can perform some additional functions and actions automatically without human intervention than bar code technology. An RFID system is equipped with a transponder, transceiver, and a data processing unit to meet enhanced identification and tracking requirements in hospital laboratories. Laboratory automated systems use RFID tags attached with patient samples for identification and smart cards to store patients’ data under a workstation that monitors the process in the laboratory. For instance, Mayo Clinic, a healthcare company, adopted RFID-enabled laboratory automation systems to minimize errors by 70%, maximize efficiency and patient safety, and reduce specimen turnaround time by 50%. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) is responsible for technologies, devices, medical or surgical equipment, support systems, and laboratory instruments, systems, and equipment. FDA sent a device recall notice to enGen Laboratory Automation System, a medical device manufacturer, for its product-enGen Track System with TCAutomation Software Version 4.2. This recall acts as a product correction notification as a laboratory system with TCA Software V4.2 may potentially cause a delay in reporting of results, aid mechanical problems, and inaccurate patient data. To reduce incidences associated with these devices and let the manufacturer communicate and inform about the instructions on how to monitor and correct the issue if it has occurred to the potentially affected enGen customers, the device recall has been made. In March 2021, SPT Labtech, a UK-based automated instrumentation manufacturer, acquired BioMicroLab for an undisclosed amount. The acquisition would strategically expand product offerings of SPT Labtech in the fields of life sciences sample mangament. BioMicroLab is a US-based robotics automation provider for life sciences laboratories. North America was the largest region in the laboratory automation systems market in 2022. Western Europe was the second largest region in the global laboratory automation systems market analysis. The regions covered in the global laboratory automation systems market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the laboratory automation systems market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The laboratory automation systems market consists of sales of clinical laboratory machines, equipment, and instruments. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The laboratory automation systems market research report is one of a series of new reports from The Business Research Company that provides laboratory automation systems market statistics, including laboratory automation systems industry global market size, regional shares, competitors with a laboratory automation systems market share, detailed laboratory automation systems market segments, market trends and opportunities, and any further data you may need to thrive in the laboratory automation systems industry. This laboratory automation systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Artificial intelligence (AI) is a simulation of the human intelligence in machines that are programmed to think and behave like humans. AI helps to complete the job quickly and with relatively few errors. The main technologies in artificial intelligence (AI) in drug discovery are deep learning and machine learning. Deep learning is a machine learning and artificial intelligence (AI) technique that mimics how humans acquire knowledge. Data science, which covers statistics and predictive modelling, incorporates deep learning as a key component. The different drug types include small molecule, large molecules and involves various types of therapies such as c, others. It is implemented in several end-users including pharmaceutical companies, biopharmaceutical companies, academic and research institutes, others. The global artificial intelligence (AI) in drug discovery market is segmented – 1) By Technology: Deep Learning, Machine Learning 2) By Drug Type: Small Molecule, Large Molecules 3) By Therapeutic Type: Metabolic Disease, Cardiovascular Disease, Oncology, Neurodegenerative Diseases, Other Therapeutics 4) By End-Users: Pharmaceutical Companies, Biopharmaceutical Companies, Academic And Research Institutes, Other End-Users The global artificial intelligence (ai) in drug discovery market size will grow from $1.04 billion in 2022 to $1.38 billion in 2023 at a compound annual growth rate (CAGR) of 31.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global artificial intelligence (ai) in drug discovery market size is expected to grow to $3.74 billion in 2027 at a CAGR of 28.4%. The rise in demand for a reduction in the overall time taken for the drug discovery process is a key driver propelling the growth of the artificial intelligence (AI) in drug discovery market. Traditionally, it takes three to five years for animal models to identify and optimize molecules before they are evaluated in humans whereas start-ups based on AI have been identifying and designing new drugs in a matter of few days or months. For instance, in 2020, the British start-up Exscientia and Japan's Sumitomo Dainippon Pharma have used artificial intelligence to produce an obsessive-compulsive disorder (OCD) medication, decreasing the development time from four years to less than one year. The reduction in overall time taken for the drug discovery process drives the artificial intelligence (AI) in drug discovery market’s growth. Major players in the artificial intelligence (AI) in drug discovery market are IBM Corporation, Microsoft, Atomwise Inc., Deep Genomics, Cloud Pharmaceuticals, Insilico Medicine, Benevolent AI, Exscientia, Cyclica and BIOAGE. The shortage of skilled professionals is expected to hamper the AI in drug discovery market. The employees have to re-train or learn new skill sets to work efficiently on the complex AI machines to get the desired results for the drug. The shortage of skills acts as a major hindrance to drug discovery through AI, discouraging companies to adopt AI-based machines for drug discovery. in 2020, according to a study by National Skills Coalition, one-third of America's workers lacked digital skills. This figure accounted for 18% of workers with only a few skills and 13% with no digital abilities. Major companies operating in the AI drug delivery market are adopting strategic collaborations to research and discover drugs using AI and are gaining significant popularity in the artificial intelligence in drug discovery market. For instance, in August 2022, Atomwise, a US-based artificial intelligence systems company, partnered with Sanofi. The partnership aimed at computationally identifying and investigating up to five pharmacological targets using the Atomwise AI-powered AtomNet technology. To find, create, and advance lead compounds for up to five Sanofi-exclusive targets, Atomwise received a $20 million upfront payment from Sanofi. Sanofi is a French pharmaceutical and healthcare company. In July 2020, Curi Bio, a leading developer of human iPSC-based platforms for drug discovery, acquired Dana Solutions for an undisclosed amount. This acquisition will give Curi Bio access to Dana's AI/ML platforms for modelling cell and tissue phenotype, automated platform for contractility analysis of beating cardiomyocyte and platform for predictive safety pharmacology. Dana Solutions is a leading AI solutions provider for the life sciences industry. North America was the largest region in the artificial intelligence (AI) in drug discovery market in 2022. Western Europe was the second largest region in the global artificial intelligence (AI) in drug discovery market share. The regions covered in the global artificial intelligence (AI) in drug discovery market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the artificial intelligence (AI) in drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The artificial intelligence (AI) in drug discovery market includes revenues earned by entities by offering AI for drug discovery. Artificial Intelligence (AI) for drug discovery is a technology that uses a simulation of the human intelligence process by machines to tackle complex problems in the drug discovery process. It helps to find new molecules to identify drug targets and develop personalized medicines in the pharmaceutical industry. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The artificial intelligence (AI) in drug discovery market research report is one of a series of new reports from The Business Research Company that provides artificial intelligence (AI) in drug discovery market statistics, including artificial intelligence (AI) in drug discovery industry global market size, regional shares, competitors with a artificial intelligence (AI) in drug discovery market share, detailed artificial intelligence (AI) in drug discovery market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) in drug discovery industry. This artificial intelligence (AI) in drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Research antibodies and reagents refer to the antibodies that bioscientists utilise as basic detection techniques. These are used to designate and distinguish particular proteins that are found within the sick cell at a particular stage of its life cycle. The main types of technologies in research antibodies and reagents are western blot, immunofluorescence, immunohistochemistry, flow cytometry, enzyme-linked immunosorbent assay (ELISA), multiplex immunosorbent assay, immunoprecipitation, and others. The western blot, also known as western blotting, is molecular biology and immunogenetics analytical technique for detecting specific proteins in a sample of tissue homogenate or extract. The different applications include proteomics, drug discovery & development, and genomics and are implemented in various sectors such as the pharmaceutical & biotechnology industry, academic & research institutes, and contract research organizations (CROs). The global research antibodies and reagents market is segmented - 1) By Technology: Western Blot, Immunofluorescence, Immunohistochemistry, Flow Cytometry, Enzyme-linked Immunosorbent Assay (ELISA), Multiplex Immunosorbent Assay, Immunoprecipitation, Other Technologies 2) By Application: Proteomics, Drug Discovery & Development, Genomics 3) By End-User: Pharmaceutical & Biotechnology Industry, Academic & Research Institutes, Contract Research Organizations (CROs) The global research antibodies and reagents market size grew from $13.19 billion in 2022 to $14.02 billion in 2023 at a compound annual growth rate (CAGR) of 6.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global research antibodies and reagents is expected to grow from $18.85 billion in 2027 at a CAGR of 7.7%. Increasing investment in medical and health research and development (R&D) is predicted to contribute to the growth of the research antibodies and reagents market. In the field of life science research, antibodies and reagents are essential components for the investigation of biological processes or causes of diseases through careful experimentation, observation, laboratory work, analysis, and testing. For instance, in April 2021, according to a report published by the Congressional Budget Office, a US-based government agency that provides budget and economic information, pharmaceutical companies will have invested $83 billion on research and development activities around the world. According to the Assobiotec publication BioInItaly 2020, healthcare is involved in 49% of the over 700 biotech firms headquartered in Italy. Thus, increasing investment in healthcare research and development will increase the utilization of the research antibodies and reagents market. Major players in the research antibodies and reagents market are Becton Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, PerkinElmer Inc., Lonza Group AG, Abcam PLC., GenScript Biotech Corporation, and Bio-Techne Corporation. Reproducibility issues of antibodies and reagents are expected to hamper the growth of the research antibodies and reagents market. Reproducibility is the ability of an experiment or calculation to be duplicated by other researchers working independently. The prevalence of irreproducible preclinical research exceeded 50%, resulting in approximately $28 billion spent on preclinical research every year. Among the irreproducible research, the largest fraction of about 36% is assigned to biological reagents, which amounts to $10 billion annually. This huge research waste is due to insufficiently validated antibodies and irreproducible reagents that are not appropriate for the target proteins. Thus, reproducibility issues with antibodies and reagents are expected to restrain market growth. Technological advancements in the area of purification of antibodies and reagents show opportunities for the growth of the research antibodies and reagents market during the forecast period. Irreproducible antibodies and reagents are a major challenge for the industry, as this will affect the outcome of the research. For instance, in July 2020, Sysmex Corporation, a Japan based diagnostic tools manufacturing company, launched antibody measurement technology for the Coronavirus (SARS-CoV-2) Antibody Lab Assay Service and Antibody Measurement Reagents. These tools were employed in a clinical performance assessment that involved IgG antibody detection. They were utilized to compare IgG antibody concentrations in relation to circulating N and S antigens between SARS-CoV-2 patients and a group of SARS-CoV-2 patients after leaving the hospital. In February 2022, Rockland Immunochemicals, Inc., a US-based company that specializes in the development of assays and basic research tools using antibodies, acquired Antibodies-Online GmbH for an undisclosed amount. Through this acquisition, Rockland, utilizing the reputable e-commerce brand, extensive supplier network, and proprietary technology stack of antibodies-online, achieves excellence in the design, development, and manufacture of antibodies and assays. Customers of each business will have access to improved capabilities supported by richer and more comprehensive data sets, enhancing their overall customer experience and boosting their go-to-market strategy. Antibodies-Online GmbH is a Germany based company that provides antibodies, reagents, and research kits to companies. North America was the largest region in the research antibodies and reagents market in 2022. The regions covered in the research antibodies and reagents analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the research antibodies and reagents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The research antibodies and reagents market consists of sales of buffers, fixatives, solvents, and enzymes. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The research antibodies and reagents market research report is one of a series of new reports from The Business Research Company that provides research antibodies and reagents market statistics, including research antibodies and reagents industry global market size, regional shares, competitors with a research antibodies and reagents market share, detailed research antibodies and reagents market segments, market trends and opportunities, and any further data you may need to thrive in the research antibodies and reagents industry. This research antibodies and reagents market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

AI in pharma refers to the use of automated algorithms to jobs that normally need human intelligence. Large datasets including disease patterns can be successfully identified by AI solutions in pharma, and they can also assist in understanding which medication formulations would be most effective for treating certain ailments. The artificial intelligence (AI) in the pharma market covered in the report is segmented by technology into context-aware processing, natural language processing, querying method, and deep learning; by drug type into the small molecule, large molecules; by application into diagnosis, clinical trial research, drug discovery, research and development, epidemic prediction. The global ai in pharma market is segmented - 1) By Technology: Context-Aware Processing, Natural Language Processing, Querying Method, Deep Learning 2) By Drug Type: Small Molecule, Large Molecules 3) By Application: Diagnosis, Clinical Trial Research, Drug Discovery, Research and Development, Epidemic Prediction The global AI in pharma market size will grow from $1.24 billion in 2022 to $1.64 billion in 2023 at a compound annual growth rate (CAGR) of 32.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the AI in pharma is expected to grow to $4.61 billion in 2027 at a CAGR of 29.4%. The growing adoption of artificial intelligence (AI) for clinical trials research is driving its demand for AI in the pharmaceutical market. To bring a new drug to the market takes on an average 10–15 years approximately and half of this time is consumed during the clinical trial phases of the drug development cycle. Hence, using AI models and analytics tools can accelerate the clinical trial phases, perception of diseases, identify suitable cases and key investigators to inform site selection, and support novel clinical study designs. For instance, in January 2020, Pfizer, an American pharmaceutical company, tied up with a biotech startupInsilico Medicine to identify drug targets. With AI tools Pfizer can speed up drug discovery and reduce drug development costs in the drug development processes. Thus, increasing the adoption of AI for clinical trials research is driving AI in the pharma market growth. Major players in the AI in pharma market are Novartis, IBM Watson, Microsoft Corporation, Merck, GNS Healthcare., Google, AstraZeneca, Atomwise, Inc., Exscientia, and Cyclica. A lack of skilled professionals may hamper the growth of artificial intelligence in the pharma market. In 2022, according to the report published by UNLEASH, a UK-based digital media platform, IBM, and Morning Consult conducted surveys of more than 1,000 tech job seekers, more than 600 tech workers, and more than 300 tech recruiters in the UK, Spain, and Germany to determine the AI skills gap in Europe and found around 28% of recruiters report having difficulty locating candidates with deep learning, machine learning, and data engineering and analytics experience. The shortage of AI skills is seen as a major barrier to the pace of technology’s adoption. In fact, 56% of senior AI professionals thought that a lack of additional, qualified AI workers was the single most important hurdle to be overcome in terms of obtaining the necessary level of AI implementation beyond business operations. Therefore, the lack of skilled professionals may hamper the growth of AI in the pharma market. Companies operating in the AI for the pharma market are introducing new AI tools that will be beneficial for the pharma companies and this is a key trend in AI in the pharma market. AI helps in quality control, predictive maintenance, waste reduction, design optimization, and process automation. For instance, in August 2022, Sanford Health, a US-based non-profit, integrated healthcare delivery system,and Sharp HealthCare, a US-based non-profit organization in healthcarepartnered with Dandelion Health, a US-based healthcare artificial intelligence (AI) company, introduced a comprehensive data platform that gives health institutions access to high-quality, representative patient data for clinical AI development. The Dandelion Platform is made to give health AI developers secure, ethical access to patient datasets which includes include images, waveforms, and structured health records, so they may make tools and products that will help patients and clinicians. In October 2021, Nurosene Health Inc., a Canada-based company focused on delivering innovative AI-based technology solutions that support mental performance and wellness acquired Netramark Incorporated for an undisclosed amount. Through this acquisition, Nurosene Health Inc aims to strengthen its capabilities in AI-based neuroscience product offerings. Netramark Incorporated is a Canada-based pharma tech company that utilizes AI, novel mathematical methods, and quantum computing to optimize new drug development, clinical trials, treatment, and diagnosis. North America was the largest region in the AI in pharma market in 2022. The regions covered in the AI in pharma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the AI in pharma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The AI in pharma market includes revenues earned by entities by implementing quality control, addressing supply chain problems in the production line, and minimising material waste. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The artificial intelligence (AI) in pharma market research report is one of a series of new reports from The Business Research Company that provides artificial intelligence (AI) in pharma market statistics, including artificial intelligence (AI) in pharma industry global market size, regional shares, competitors with artificial intelligence (AI) in pharma market share, detailed artificial intelligence (AI) in pharma market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) in pharma industry. This artificial intelligence (AI) in pharma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Next-generation sequencing is a sequencing technology that offers ultra-high throughput, scalability, and speed. The technology is used to determine the genetic variation associated with diseases or other biological phenomena. The main products in the next-generation sequencing market are NextSeq systems, MiniSeq systems, NovaSeq systems, iSeq 100 systems, ion PGM Systems, Ion Proton systems, ion GeneStudio S5 systems, PacBio RS II Systems, sequel systems, and others. The MiniSeq system merges load-and-go operation with an intuitive user interface for a fast, easy NGS workflow. The MiniSeq System integrates clonal amplification, sequencing through synthesis, and base calling into a single benchtop instrument, preventing the requirement for additional equipment. The various technologies in next-generation sequencing are sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, nanopore sequencing, and other sequencing technologies that are used in diagnostics, drug discovery, and other applications. The global next generation sequencing market is segmented - 1) By Product: NextSeq Systems, MiniSeq Systems, NovaSeq Systems, iSeq 100 Systems, Ion PGM Systems, Ion Proton Systems, Ion GeneStudio S5 Systems, PacBio RS II Systems, Sequel Systems, Other Products 2) By Technology: Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing, Nanopore Sequencing, Other Sequencing Technologies 3) By Application: Diagnostics, Drug Discovery, Other Applications The global next generation sequencing market size will grow from $9.22 billion in 2022 to $10.44 billion in 2023 at a compound annual growth rate (CAGR) of 13.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global next generation sequencing is expected to grow to $17.32 billion in 2027 at a CAGR of 13.5%. The growing number of cases with chronic conditions such as cancer, AIDS, and thalassemia contributed to the growth of the next-generation sequencing market. Chronic illnesses and disorders are on the rise around the world, an aging population and shifts in social behavior lead to a gradual increase in these widespread and expensive long-term medical issues. Next-generation sequencing (NGS) is a versatile development tool utilized by researchers and clinicians across various cancer studies to recognize biomarkers that give guidance on treatments. The prevalence of chronic diseases is also expected to increase significantly, according to the World Health Organization. Hence, the increase in the number of chronic disease cases will increase the requirement for NGS sequencing and boosts revenues for the growth of next generation sequencing market. Major players in the next generation sequencing market are Illumina Inc., Thermo Fisher Scientific Inc., BGI Group, Agilent Technologies Inc., Qiagen N.V., Hoffmann-La Roche AG, Eurofins Scientific, Oxford Nanopore Technologies, Pacific Biosciences, and 10x Genomics. The high cost associated with next generation sequencing technologies is a key factor hampering the growth of the next-generation sequencing market. The next-generation sequencing market is facing challenges as many people find it difficult to afford the test due to the high cost. Consumables used for sequencing are the costliest portion of testing (68–72% of total cost) as machinery prices are higher in instances of rare disease. According to a review published on economic evaluations of exome and genome sequencing, the cost of next-generation genome sequencing ranges from $1906 to $24,810 for a single test. Therefore, the high cost of next-generation sequencing is anticipated to restrict market growth over the forecast period. Technological advances are shaping the next generation sequencing market. Major companies operating in the sequencing industry are focusing on developing technologically advanced solutions for next-generation sequencing. For instance, in 2020, Thermo Fisher Scientific introduced hematology-oncology assays for the Ion Torrent Genexus System, which authorize simultaneous analysis of DNA mutations and RNA fusion transcripts in myeloid samples in a single day and also enabled further in which turnaround times for next-generation sequencing (NGS) results could be reduced to less than 24 hours. It also offers researchers the ability to profile 40 DNA targets and 29 fusion driver genes, authorizing observing more than 600 fusion isotypes to recognize biomarkers associated with myeloproliferative neoplasm, acute myeloid leukemia. North America was the largest region in the next generation sequencing market in 2022. Asia-Pacific was the second largest region in the global next generation sequencing market share. The regions covered in the global next generation sequencing market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the next generation sequencing market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The next generation sequencing market consits of sales of genetic sequencing equipment with advanced features and technologies such as ion semiconductor sequencing, nano-pore sequencing, single-molecule real-time sequencing, and other technologies that are used for next generation sequencing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The next generation sequencing market research report is one of a series of new reports from The Business Research Company that provides next generation sequencing market statistics, including next generation sequencing industry global market size, regional shares, competitors with a next generation sequencing market share, detailed next generation sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation sequencing industry. This next generation sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Transcriptomics/RNA analysis is a study of the transcriptome under specific circumstances, environment, or in a specific cell using high-throughput methods. The main types of products in the RNA analysis/ transcriptomics market are reagents/consumables, instruments, and software. It is implemented in various areas including clinical diagnostics, drug discovery, toxicogenomics, comparative transcriptomics, and RNA interference. Major technology involved in RNA analysis/ transcriptomics are microarrays, sequencing, polymerase chain reaction RNA interference. RNA analysis is used in clinical diagnosis to detect different RNA species, and pathogen RNA splice variants among others useful in the diagnosis of diseases. The global RNA analysis or transcriptomics market is segmented - 1) By Product: Reagents/Consumables, Instruments, Software 2) By Technology, Microarrays, Sequencing, Polymerase Chain Reaction RNA Interference 3) By Application: Clinical Diagnostics, Drug Discovery, Toxicogenomics, Comparative Transcriptomics, RNA Interference The global RNA analysis/ transcriptomics market size grew from $5.96 billion in 2022 to $6.76 billion in 2023 at a compound annual growth rate (CAGR) of 13.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of RNA analysis/ transcriptomics is expected to grow to $11.33 billion in 2027 at a CAGR of 13.8%. The increasing demand for personalized medicine is expected to drive the growth of the RNA analysis/ transcriptomics market in the coming years. Personalized medicine refers to the customizing of medical treatment to each patient's unique characteristics. If scientists can implement the necessary practices and processes for personalized clinical care, RNA-Seq will be well-positioned to handle the massive clinical workload. According to the Personalized Medicine Report 2020 published by the Personalized Medicine Coalition (PMC), the number of personalized medicines in the market more than doubled between 2016 and 2020 in the USA. Therefore, the growing demand for personalized medicines propels the growth of the RNA analysis market. Major players in the RNA analysis/ transcriptomics market are Affymetrix Inc., Agilent Technologies Inc., Bio-Rad Laboratories Inc., GE Healthcare, Illumina Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd., Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc., Fluidigm Corporation, Promega Corporation, and Biomereiux SA. Technological advancements and innovations in RNA analysis are an emerging trend in the RNA analysis/ transcriptomics market. Technologies such as next-generation sequencing (NGS) and RNA interference (RNAi) improved precision and accuracy, which help researchers analyze the transcriptional activity. For instance, Next-generation sequencing developed by Illumina is successfully used in fragmenting DNA/RNA into multiple pieces, adding adapters, sequencing the libraries, and reassembling them to form a genomic sequence. In October 2020, 10x Genomics, a startup based in the USA acquired Cartana for an amount of $41.2 million. The acquisition of Cartana is expected to strengthen its approach to developing technologically advanced products. Cartana is a Sweden-based biotechnology player involved in developing in situ RNA analysis technology. North America was the largest region in the RNA analysis/transcriptomics market in 2022. This region is expected to be the fastest-growing region in the forecast period. The regions covered in the RNA analysis/ transcriptomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the RNA analysis/ transcriptomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The RNA analysis/ transcriptomics market includes revenues earned by entities by providing services such as Whole-Genome Sequencing, Whole-Exome Sequencing, Targeted Sequencing, Microarray Analysis, Sanger Sequencing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced.It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The RNA analysis/ transcriptomics market research report is one of a series of new reports from The Business Research Company that provides RNA analysis/ transcriptomics market statistics, including RNA analysis/ transcriptomics industry global market size, regional shares, competitors with a RNA analysis/ transcriptomics market share, detailed RNA analysis/ transcriptomics market segments, market trends and opportunities, and any further data you may need to thrive in the RNA analysis/ transcriptomics industry. This RNA analysis/ transcriptomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.